A PHASE-II TRIAL OF IFOSFAMIDE MESNA WITH DOXORUBICIN FOR MALIGNANT MESOTHELIOMA

被引:19
作者
CARMICHAEL, J [1 ]
CANTWELL, BMJ [1 ]
HARRIS, AL [1 ]
机构
[1] UNIV NEWCASTLE UPON TYNE,NEWCASTLE GEN HOSP,REG RADIOTHERAPY CTR,DEPT CLIN ONCOL,NEWCASTLE TYNE NE4 6BE,ENGLAND
来源
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1989年 / 25卷 / 05期
关键词
D O I
10.1016/0277-5379(89)90141-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:911 / 912
页数:2
相关论文
共 5 条
[1]  
AISNER J, 1981, SEMIN ONCOL, V8, P335
[2]  
ALBERTS SS, 1988, J NATL CANCER I, V80, P698
[3]  
CANTWELL BMJ, 1988, CANCER CHEMOTH PHARM, V21, P49
[4]   EFFICACY OF IFOSFAMIDE IN REFRACTORY MALIGNANT DISEASES AND UROPROTECTION BY MESNA - RESULTS OF A CLINICAL-PHASE II-STUDY WITH 151 PATIENTS [J].
SCHEULEN, ME ;
NIEDERLE, N ;
BREMER, K ;
SCHUTTE, J ;
SEEBER, S .
CANCER TREATMENT REVIEWS, 1983, 10 :93-101
[5]  
SORENSEN PG, 1985, CANCER TREAT REP, V69, P1431